Neuberger Berman Group
ESPR

Neuberger Berman Group’s Esperion Therapeutics ESPR Stock Holding History

Neuberger Berman Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.6K Buy
13,798
+956
+7% +$2.67K ﹤0.01% 2295
2026
Q1 		$35.2K Sell
12,842
-1,613
-11% -$5.11K ﹤0.01% 2127
2025
Q4 		$53.5K Buy
+14,455
New +$46.7K ﹤0.01% 2052
2025
Q3 		– Sell
-14,250
Closed -$14K – 2070
2025
Q2 		$14K Buy
14,250
+1,894
+15% +$1.9K ﹤0.01% 2036
2025
Q1 		$17.8K Buy
12,356
+1,635
+15% +$3.01K ﹤0.01% 1944
2024
Q4 		$23.6K Hold
10,721
– – ﹤0.01% 1907
2024
Q3 		$17.7K Buy
+10,721
New +$21.6K ﹤0.01% 1905
2023
Q3 		– Sell
-15,899
Closed -$22.1K – 1830
2023
Q2 		$22.1K Buy
+15,899
New +$22.2K ﹤0.01% 1773
2018
Q2 		– Sell
-18,000
Closed -$1.3M – 1720
2018
Q1 		$1.3M Buy
+18,000
New +$1.32M ﹤0.01% 1109
2017
Q3 		– Sell
-16,500
Closed -$764K – 1613
2017
Q2 		$764K Buy
+16,500
New +$607K ﹤0.01% 1219
2015
Q3 		– Sell
-20,341
Closed -$1.66M – 1545
2015
Q2 		$1.66M Buy
20,341
+12,466
+158% +$1.22M ﹤0.01% 1103
2015
Q1 		$729K Buy
+7,875
New +$508K ﹤0.01% 1269
2013
Q4 		– Sell
-22,550
Closed -$425K – 1626
2013
Q3 		$425K Buy
+22,550
New +$379K ﹤0.01% 1348

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Neuberger Berman Group's ESPR Position: Q2 2026 in Review

Neuberger Berman Group increased its Esperion Therapeutics (ESPR) stake by 7.4% in Q2 2026, buying an estimated $2.67K and bringing the position to 13,798 shares worth $43.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2295.

Neuberger Berman Group first reported a position in ESPR in Q3 2013 and has held it in 13 quarters since. The position peaked at $1.66M in Q2 2015. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Neuberger Berman Group held 13,798 shares of Esperion Therapeutics worth $43.6K as of Q2 2026.
  • Neuberger Berman Group bought 956 Esperion Therapeutics shares in Q2 2026, an estimated $2.67K.
  • Esperion Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2295 holding.
  • Neuberger Berman Group first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 13 quarters since.
  • Neuberger Berman Group's Esperion Therapeutics position peaked at $1.66M in Q2 2015.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.